Lipid management continues to be an essential component in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). For the past decade, clinical practice guidelines have gone back and forth about optimal treatment goals but guidelines all agree that statins should be used as the preferred initial therapy. However, there is still a lack of clarity about the optimal add-on therapies. The newest LDL-lowering therapy is inclisiran, a small interfering RNA (siRNA) that targets the PCSK9 pathway.
Guest Authors: Joshua O. Holmes, PharmD, MS and Amanda Schartel, PharmD, BCACP
Music by Good Talk